within Pharmacolibrary.Drugs.ATC.B;

model B03AA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.12,
    Cl             = 0.05 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,
    adminCount     = 1,
    Vd             = 0.0008,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 900
  );

  annotation(Documentation(
    info ="<html><body><p>Ferrous glycine sulfate is an iron supplement used to treat or prevent iron deficiency anemia. It is a chelated compound of iron and glycine, designed for improved gastrointestinal absorption and reduced gastrointestinal irritation compared to other iron salts. It has been marketed and used in several countries but is not available in all regulatory regions.</p><h4>Pharmacokinetics</h4><p>No published human pharmacokinetic (PK) models or parameterizations were found in the literature for ferrous glycine sulfate. Estimates below are based on standard oral iron pharmacokinetics in healthy adult populations.</p><h4>References</h4><ol><li><p>Hershko, C, et al., &amp; Souroujon, M (2007). Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis. <i>Acta haematologica</i> 118(1) 19–26. DOI:<a href=&quot;https://doi.org/10.1159/000101701&quot;>10.1159/000101701</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17426393/&quot;>https://pubmed.ncbi.nlm.nih.gov/17426393</a></p></li><li><p>Paulson, SK, et al., &amp; Chavan, A (2022). Effect of Phosphate Binders and a Dietary Iron Supplement on the Pharmacokinetics of a Single Dose of Vadadustat in Healthy Adults. <i>Clinical pharmacology in drug development</i> 11(4) 475–485. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1033&quot;>10.1002/cpdd.1033</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35172045/&quot;>https://pubmed.ncbi.nlm.nih.gov/35172045</a></p></li><li><p>Kokado, Y, et al., &amp; Kondo, K (2021). In Vitro and Clinical Pharmacokinetic Studies of the Effects of Iron-containing Agents on Vadadustat, an Oral Hypoxia-inducible Factor-Prolyl Hydroxylase Inhibitor. <i>Clinical therapeutics</i> 43(8) 1408–1418.e5. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2021.06.013&quot;>10.1016/j.clinthera.2021.06.013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34511184/&quot;>https://pubmed.ncbi.nlm.nih.gov/34511184</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B03AA01;
